R1 RCM Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCM research report →
Range $14 – $25
Price Chart
About the company
R1 RCM Inc. leverages technology to provide solutions that both optimize the patient experience and bolster the financial performance of hospitals, health systems, and medical groups. Its core offering is comprehensive revenue cycle management (RCM), meticulously designed to address the entire spectrum of financial complexities faced by healthcare providers.
- CEO
- Lee Rivas
- IPO
- 2017
- Employees
- 29,400
- HQ
- Murray, UT, US
Get TickerSpark's AI analysis on RCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.04B
- P/E
- 1811.39
- Fwd P/E
- 49.34
- PEG
- -2.40
- P/S
- 2.68
- P/B
- 2.18
- EV/EBITDA
- 17.86
- Div Yield
- 0.00%
- Gross Margin
- 21.49%
- Op Margin
- 6.56%
- Net Margin
- 0.15%
- ROE
- 0.12%
- ROIC
- 0.49%
Latest fiscal year · YoY change
- Revenue
- $2.25B+24.8%
- Gross Profit
- $484.50M+34.1%
- Op Income
- $147.90M
- Net Income
- $3.30M+105.7%
- EPS
- $0.01+104.9%
- OCF Growth
- +3535.4%
- FCF Growth
- +329.8%
- 52W High
- $14.31
- 52W Low
- $14.31
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.84
- RSI (14)
- 75
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
R1 RCM reported a solid Q2 with revenue and adjusted EBITDA ahead of expectations, but withdrew full-year guidance after announcing a take-private deal and flagged a significant second-half hit from the Ascension cyber outage.· August 7, 2024
- Q2 revenue was $627.9 million and adjusted EBITDA was $156.1 million, with total revenue up 12% year over year.
- Management said underlying trends were strong despite the Change Healthcare and Ascension disruptions, and Q2 results were ahead of internal expectations.
- Acclara integration is progressing at or ahead of plan, and the company says it remains confident in its synergy goals.
- R1 completed onboarding of over 1,900 associates for its largest new end-to-end customer and expects revenue ramping in the second half.
- No 2024 guidance was provided because of the pending transaction, but management quantified a $75 million to $95 million full-year revenue impact from the Ascension outage and $10 million to $15 million of incremental second-half costs.
Second-quarter revenue was $627.9 million, up 12% year over year, and adjusted EBITDA was $156.1 million. Net operating fees were $374.6 million, up about 5% year over year, while Modular and Other revenue was $231.6 million, up 35% year over year. Incentive fees were $21.7 million, slightly below expectations due to a $4 million impact from outages. Non-GAAP cost of services was about $421 million, up roughly $57 million year over year, and non-GAAP SG&A was $50.8 million, down about $3 million. Cash and cash equivalents were $163 million at June 30, cash from operations was $36.8 million, and net debt was $2.1 billion. Looking ahead, the company is not providing 2024 guidance due to the announced transaction, but expects the Ascension outage to reduce full-year revenue by $75 million to $95 million, mostly as a timing shift into 2025, and expects $10 million to $15 million of incremental costs in the second half.
Lee Rivas emphasized that R1 sees strong demand for its platform and believes it is the leading automation and revenue cycle partner because of its scale, data, and technology. He pointed to the successful onboarding of more than 1,900 associates for a major new customer, continued progress on Acclara integration, and new cross-sell wins as evidence that the company is executing well. His tone was confident and constructive, even while acknowledging the operational disruption from the Ascension cyberattack.
Jennifer Williams said the quarter was ahead of expectations despite disruption from Change Healthcare and Ascension, and highlighted cost discipline as a key offset to the revenue impact. She cited $627.9 million of revenue, $156.1 million of adjusted EBITDA, $421 million of non-GAAP cost of services, $50.8 million of non-GAAP SG&A, and $34.3 million of other expenses, including $14 million of integration-related costs, $6.3 million for a one-time vendor termination fee, and about $8 million of advisory fees. On cash and liquidity, she noted $163 million of cash, $36.8 million in operating cash flow, $2.1 billion of net debt, and about $682 million of liquidity.
There was no Q&A, because management said it would not take questions after the prepared remarks due to the pending transaction. The main incremental disclosure in the remarks was the quantified Ascension impact: $75 million to $95 million of full-year revenue delay, mostly shifting into 2025, plus $10 million to $15 million of second-half incremental costs.
The quarter showed solid underlying demand, with 12% revenue growth, strong modular growth, and adjusted EBITDA ahead of expectations. Management also described ongoing customer wins, cross-sell opportunities, and progress on AI, automation, and Acclara integration as sources of continued momentum.
The biggest near-term risk is the Ascension outage, which management said will create a significant second-half revenue and cost impact and push much of the recovery into 2025. The company also remains exposed to cyber-related disruptions, customer attrition in physician services, and deal-related uncertainty because it is in the middle of a take-private transaction and withdrew guidance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.5%
- Shares Outstanding
- 422.39M
- Float Shares
- 293.71M
of shares held by institutions
265 13F filers
Buy/sell ratio 0.27. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 16.49M | ▼ 182.07K |
| Credit Suisse AG/ | 307.10K | ▼ 13.25K |
| Point72 Middle East Fze | 131.43K | ▲ 131.43K |
| Crystalline Management Inc. | 65.40K | ▲ 65.40K |
| Cetera Advisor Networks LLC | 11.40K | ▼ 510 |
| Planning Capital Management Corp | 1.34K | 0 |
Held by 10 ETFs
Biggest fund positions in RCM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 24 | New Mountain Capital, L.L.C. | other | 11,075,180 |
| Nov 19, 24 | DILL DAVID M | sell | 49,522 |
| Nov 19, 24 | HENNEMAN JOHN B III | sell | 87,765 |
| Nov 19, 24 | HENNEMAN JOHN B III | sell | 515,715 |
| Nov 19, 24 | Ashdown Clay | other | 0 |
| Nov 19, 24 | Wexler Erik G. | other | 0 |
| Nov 19, 24 | Nakis Dominic | other | 0 |
| Nov 19, 24 | Bundy Scanlan Agnes | sell | 33,014 |
| Nov 19, 24 | FLANAGAN JOSEPH GERARD | other | 98,238 |
| Nov 19, 24 | FLANAGAN JOSEPH GERARD | sell | 944,236 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RCM coverage
Recent articles, reports, and earnings notes.
No research on RCM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCM report →IKS Health Completes Acquisition of TruBridge
gurufocus.com · Jul 9
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction
businesswire.com · Jun 19
RCM Services Provider Fellow Health Partners Announces Strategic Investment from Cleargate Capital Partners
businesswire.com · Jun 16
Cosentus Invests in Accreda Healthcare Management — An Anesthesia-Exclusive RCM Provider
businesswire.com · Sep 5
TowerBrook and CD&R Complete Acquisition of R1 RCM
globenewswire.com · Nov 19
Here's What Key Metrics Tell Us About R1 RCM INC (RCM) Q3 Earnings
zacks.com · Nov 5
R1 RCM Inc. (RCM) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN and RCM on Behalf of Shareholders
accesswire.com · Nov 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.